Society of Hematologic Oncology Annual Meeting (SOHO) | Conference

Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel

September 7th 2023

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7th 2023

No difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hematopoietic stem cell transplantation in elderly patients over the age of 60 with acute myeloid leukemia in first complete remission.

Dr Kantarjian on the Predictive Value of Early Responses to Ponatinib in CP-CML

September 7th 2023

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

Understanding How to Best Measure MRD Negativity in Ph+ ALL

September 7th 2023

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL

September 7th 2023

Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.

Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML

September 7th 2023

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

Health Outcomes in Hematologic Malignancies Impacted By Insurance, Marital, and Economic Status

September 7th 2023

Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.

Luspatercept Displays Superiority Over ESA in RBC Transfusion-Dependent MDS

September 7th 2023

The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

September 7th 2023

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL

September 6th 2023

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Outcomes With Pediatric-Inspired Regimens Warrant Further Exploration in AYA PH- ALL

September 6th 2023

Varying outcomes were observed among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were treated with pediatric-inspired protocols vs adult chemotherapy regimens.

Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma

September 6th 2023

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

Long-Term Treatment With Ibrutinib Is Possible in Newly Diagnosed CLL/SLL

October 13th 2022

Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.

Ibrutinib Plus Venetoclax Improves Undetectable MRD Responses in Elderly, Unfit CLL

October 13th 2022

Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.

Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML

October 9th 2022

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

Ivosidenib/Venetoclax/Azacitidine Proves Tolerable, Strengthens Survival in AML

October 6th 2022

Ivosidenib plus venetoclax with or without azacitidine showed an expected and tolerable safety profile with durable responses and a prolonged survival rate across acute myeloid leukemia disease groups.

ASTX727/Venetoclax Combo Is Safe and Effective in First-Line and Relapsed/Refractory AML

October 5th 2022

Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.

Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL

October 3rd 2022

Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Momelotinib Improves OS in Patients With Myelofibrosis and Low Platelet Counts

October 3rd 2022

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Belantamab Mafodotin Combination Elicits Encouraging ORRs in Relapsed/Refractory Multiple Myeloma

October 1st 2022

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.